Lauren Myrick, APRN
Adult Health · Bowling Green, KYNPI 1215206123
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,188 of the $2,522 with a category attached, or 86.8%. It is spread thinly across 34 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations.
Across 123 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$549
- AbbVie$306
- Accord Healthcare, Inc.$228
- Urogen Pharma, Inc.$220
- Pfizer$166
- Johnson & Johnson$133
- plus $921 from 28 others
What the payments were for
- Food & beverage$2,18887%
- Education$33413%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 26 | $549 |
| AbbVie | 18 | $306 |
| Accord Healthcare, Inc. | 10 | $228 |
| Urogen Pharma, Inc. | 9 | $220 |
| Pfizer | 9 | $166 |
| Johnson & Johnson | 4 | $133 |
| C. R. Bard, Inc. & Subsidiaries | 4 | $102 |
| Tolmar, Inc. | 4 | $89 |
| Boston Scientific | 5 | $74 |
| Calyxo, Inc. | 3 | $60 |
| Endo Pharmaceuticals Inc. | 2 | $46 |
| Sumitomo Pharma America, Inc. | 3 | $46 |
| 180 Medical, Inc. | 2 | $44 |
| Janssen Scientific Affairs, LLC | 1 | $38 |
| Olympus America Inc. | 2 | $37 |
| Bayer | 2 | $35 |
| Antares Pharma, Inc. | 2 | $33 |
| KARL Storz Endoscopy-america | 1 | $30 |
| Abiomed | 1 | $28 |
| Cycle Pharmaceuticals Inc | 1 | $24 |
| Convatec Inc. | 1 | $24 |
| AstraZeneca | 1 | $21 |
| Coloplast | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Medtronic | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Urovant Sciences Inc | 1 | $17 |
| Halozyme Inc | 1 | $17 |
| Rochester Medical Corporation | 1 | $16 |
| Axonics, Inc. | 1 | $16 |
| Valencia Technologies Corporation | 1 | $14 |
| Myovant Sciences Inc. | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $12 |
| Tolmar Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$2,522 in reported general payments places this provider in the 80th percentile of 170 adult health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 254 | $166,218 |
| GemtesaVibegron | 84 | $42,501 |
| Mirabegron ErMirabegron | 41 | $32,022 |
| Tamsulosin Hcl | 1,330 | $18,055 |
| ElmironPentosan Polysulfate Sodium | 11 | $11,991 |
| Finasteride | 1,035 | $11,719 |
| Solifenacin Succinate | 162 | $4,728 |
| Estradiol | 57 | $4,003 |
| Testosterone Cypionate | 129 | $3,413 |
| Testosterone | 22 | $3,031 |
| Trimethoprim | 38 | $2,382 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $1,757 |
| Dutasteride | 55 | $1,640 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 67 | $1,636 |
| NitrofurantoinNitrofurantoin Macrocrystal | 79 | $1,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $549 | $166,218254 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $46 | $42,50184 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 170 adult health providers in Kentucky.
Other adult health in Bowling Green
- Carrie Clifford-BennettGeorgetown$730K
- Stephanie FlaspoehlerLouisville$174K
- Kimberly VesselsBrandenburg$58K
- Heidi GalloLouisville$15K
- Amy BakerPaducah$14K
- Joyce JohnsonElizabethtown$12K
- Karen EastridgeLouisville$10K
- Seon Hui BalistrereHopkinsville$8K
- Barbara CarpenterLouisville$8K
- Jennifer ThomasPaducah$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.